Prognostic genes of breast cancer revealed by gene co-expression network analysis.

The aim of the present study was to identify genes that may serve as markers for breast cancer prognosis by constructing a gene co-expression network and mining modules associated with survival. Two gene expression datasets of breast cancer were downloaded from ArrayExpress and genes from these datasets with a coefficient of variation >0.5 were selected and underwent functional enrichment analysis with the Database for Annotation, Visualization and Integration Discovery. Gene co-expression networks were constructed with the WGCNA package in R. Modules were identified from the network via cluster analysis. Cox regression was conducted to analyze survival rates. A total of 2,669 genes were selected, and functional enrichment analysis of them revealed that they were mainly associated with the immune response, cell proliferation, cell differentiation and cell adhesion. Seven modules were identified from the gene co-expression network, one of which was found to be significantly associated with patient survival time. Expression status of 144 genes from this module was used to cluster patient samples into two groups, with a significant difference in survival time revealed between these groups. These genes were involved in the cell cycle and tumor protein p53 signaling pathway. The top 10 hub genes were identified in the module. The findings of the present study could advance the understanding of the molecular pathogenesis of breast cancer.

[1]  T. Rajkumar,et al.  Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole , 2013, Cellular Oncology.

[2]  T. Mizuno,et al.  The Mcm2–7-interacting domain of human mini-chromosome maintenance 10 (Mcm10) protein is important for stable chromatin association and origin firing , 2017, The Journal of Biological Chemistry.

[3]  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer , 2009, British Journal of Cancer.

[4]  B. Park,et al.  Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women , 2013, PloS one.

[5]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[6]  R. M. Simpson,et al.  Functional Analysis of Prognostic Gene Expression Network Genes in Metastatic Breast Cancer Models , 2014, PloS one.

[7]  Xin Zheng,et al.  TPX2 as a novel prognostic biomarker for hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  Hung-Wei Pan,et al.  Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer , 2017, OncoTargets and therapy.

[9]  N. Pavlidis,et al.  Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Pavey,et al.  In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis , 2016, Oncogene.

[11]  R. Albulescu.  Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. , 2013, Biomarkers in medicine.

[12]  Hai-Meng Zhou,et al.  Use of Serum Circulating Ccnb2 in Cancer Surveillance , 2010, The International journal of biological markers.

[13]  Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma , 2018, Cell Death & Disease.

[14]  Ping Chen,et al.  ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth , 2016, Oncotarget.

[15]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[16]  K. Kontzoglou,et al.  Correlation between Ki67 and Breast Cancer Prognosis , 2013, Oncology.

[17]  G. Viglietto,et al.  Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells. , 2013, Blood.

[18]  Jingting Jiang,et al.  The Role of Kif4A in Doxorubicin-Induced Apoptosis in Breast Cancer Cells , 2014, Molecules and cells.

[19]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[20]  Qing-lin Han,et al.  MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. , 2015, Oncology reports.

[21]  J. Hartman,et al.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. , 2009, International journal of oncology.

[22]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[23]  Tsung-Hsien Chang,et al.  Ubiquitin-Conjugating Enzyme UBE2C Is Highly Expressed in Breast Microcalcification Lesions , 2014, PloS one.

[24]  Peter A Dervan,et al.  Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. , 2007, Cancer genomics & proteomics.

[25]  Christopher P. Arthur,et al.  Insights into Antiparallel Microtubule Crosslinking by PRC1, a Conserved Nonmotor Microtubule Binding Protein , 2010, Cell.

[26]  A. Redig,et al.  Breast cancer as a systemic disease: a view of metastasis , 2013, Journal of internal medicine.

[27]  F. Qiu,et al.  Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis , 2014, BMC Cancer.

[28]  J. Silverman,et al.  HER2 in Breast Cancer: A Review and Update , 2014, Advances in anatomic pathology.

[29]  Q. Ni,et al.  The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation , 2013, Medical Oncology.

[30]  Peter A. Fasching,et al.  AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection , 2015, PloS one.

[31]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[32]  N. Lehman,et al.  Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma , 2008, Modern Pathology.

[33]  Wen Song,et al.  Identification of key gene modules and pathways of human breast cancer by co-expression analysis , 2018, Breast Cancer.

[34]  Ki-Chun Yoo,et al.  PTTG1 Oncogene Promotes Tumor Malignancy via Epithelial to Mesenchymal Transition and Expansion of Cancer Stem Cell Population* , 2012, The Journal of Biological Chemistry.

[35]  A. Sokolov,et al.  Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance , 2014, Molecular Cancer Research.

[36]  E. Thompson,et al.  BRCA and beyond: a genome-first approach to familial breast cancer risk assessment. , 2011, Discovery medicine.

[37]  Ming Liu,et al.  Bioinformatics analysis of RNA sequencing data reveals multiple key genes in uterine corpus endometrial carcinoma , 2017, Oncology letters.

[38]  Y. Jeng,et al.  ASPM Is a Novel Marker for Vascular Invasion, Early Recurrence, and Poor Prognosis of Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[39]  J. Weitzel.  The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. , 2015, Surgical oncology clinics of North America.

[40]  R. Ni,et al.  Enhanced expression of early mitotic inhibitor-1 predicts a poor prognosis in esophageal squamous cell carcinoma patients , 2016, Oncology letters.

[41]  Y. Yen,et al.  HP1β Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy , 2015, PloS one.

[42]  K Nasmyth,et al.  Viewpoint: Putting the Cell Cycle in Order , 1996, Science.

[43]  K. Khanna,et al.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis , 2016, Oncogene.

[44]  G. Hall,et al.  ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival , 2011, British Journal of Cancer.

[45]  Lei Zhang,et al.  Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer , 2015, Breast Cancer Research and Treatment.

[46]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[47]  Shuai Li,et al.  Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center , 2015, PloS one.

[48]  C. B. Shuster,et al.  PRC1 controls spindle polarization and recruitment of cytokinetic factors during monopolar cytokinesis , 2012, Molecular biology of the cell.

[49]  Chuiguo Huang,et al.  Identification of genes associated with castration-resistant prostate cancer by gene expression profile analysis , 2017, Molecular medicine reports.

[50]  Noriaki Ohuchi,et al.  Prediction of breast cancer prognosis by gene expression profile of TP53 status , 2008, Cancer science.

[51]  David Cameron,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Oncogene.

[52]  Peir-In Liang,et al.  MCM10 overexpression implicates adverse prognosis in urothelial carcinoma , 2016, Oncotarget.

[53]  Xin-cheng Liu,et al.  TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT , 2015, Digestive Diseases and Sciences.

[54]  L. O’Driscoll,et al.  Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. , 2013, Carcinogenesis.

[55]  Rachel V. Stankowski,et al.  Breast cancer biomarkers: Risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence , 2014 .

[56]  G. Colditz,et al.  COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin , 2011, Breast Cancer Research and Treatment.

[57]  Yongjun Tan,et al.  FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. , 2013, Cancer letters.

[58]  Wei Zhang,et al.  Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation , 2016, OncoTargets and therapy.

[59]  A. C. Pereira,et al.  Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. , 2007, Cancer research.

[60]  K. Kumamoto,et al.  Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis , 2017, Oncology letters.

[61]  I. Bièche,et al.  Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. , 2008, Journal of molecular endocrinology.

[62]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[63]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[64]  Bin Liu,et al.  Identification of key genes associated with bladder cancer using gene expression profiles , 2017, Oncology letters.

[65]  Johan Hartman,et al.  FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance , 2010, Oncogene.

[66]  Q. Song,et al.  TPX2 promotes migration and invasion of human breast cancer cells. , 2015, Asian Pacific journal of tropical medicine.

[67]  Jeffrey C Miecznikowski,et al.  Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways , 2010, BMC Cancer.

[68]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[69]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[70]  K. Najarian,et al.  Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. , 2012, Future oncology.

[71]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[72]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[73]  Lara J. Monteiro,et al.  FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells , 2010, Molecular Cancer Research.

[74]  Ümit V. Çatalyürek,et al.  NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels , 2014, Cancer biology & therapy.

[75]  S. McGuire.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.